...
首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Efficacy and safety profile of a herbal drug containing nasturtium herb and horseradish root in acute sinusitis, acute bronchitis and acute urinary tract infection in comparison with other treatments in the daily practice/results of a prospective coh
【24h】

Efficacy and safety profile of a herbal drug containing nasturtium herb and horseradish root in acute sinusitis, acute bronchitis and acute urinary tract infection in comparison with other treatments in the daily practice/results of a prospective coh

机译:含有金莲花和辣根的草药在急性鼻窦炎,急性支气管炎和急性尿路感染中的疗效和安全性,与其他治疗方法的比较/前瞻性研究结果

获取原文
获取原文并翻译 | 示例

摘要

PATIENTS AND METHODS: In a prospective cohort study from 251 centers in Germany patients with age of 4 years or above who were treated due to acute sinusitis, bronchitis or urinary tract infections (UTI) in the period from 1st March 2004 - 30th July 2005, were elected. They were included in the study analysis, if they had no exclusion criteria (severe diseases, need for antibiotic therapy, participation in another trial) and came to the final investigation. The patients were treated either with the nasturtium herb and horseradish root containing herbal drug Angocin Anti-Infekt N (test group, n = 1223) or with standard antibiotic therapy (control group, n = 426). Treatment, dosage and treatment duration were determined by the physician in accordance with the patient. 536 subjects (408 test, 128 control patients) suffered from acute sinusitis, 634 subjects (469 test, 165 control patients) from acute bronchitis and 479 subjects (346 test, 133 control patients) from UTI. At study start and end the severityof the symptoms were judged by the investigator and quantified with 4 scores (0 = no symptom, 3 severe symptom). During the treatment information on use of medication, concomitant procedures and adverse events (AEs) in a patient diary. At the end of the study (disease free or after 7-14 days) the patient returned to the investigator, who recorded the vital parameters, finally judged the treatment efficacy and potential persisting symptoms on the basis of score values. Primary efficacy criterion was the change of the complaints quantified by the change of the relative symptom score averaged over all symptoms and related to the baseline value. RESULTS: In patients with acute sinusitis the mean relative reduction of the averaged symptom score was 81.3% for the test group and 84.6% for the control group, in patients with acute bronchitis the mean reduction was 78.3% for the test group and 80.3% for the control group, in patients with UTI 81.2% for the test group and 87.9% for the control group. The 95% confidenceinterval for the difference of the expected reductions between test and control group was -8.5% to 1.8% for acute sinusitis, 7.6% to 3.6% for acute bronchitis and -13.1% to -0.1% for UTI. Non-inferiority of the test treatment, i.e. if the lower limit of the 95% confidence interval is greater than 10%, could be stated for acute sinusitis and bronchitis. In UTI the non-inferiority level was exceeded only by 3%. Complementary procedures were less in the test group than in the control group. For 1.5 % of test patients and 6.8% of control patients AEs were observed CONCLUSION: Therapy with the herbal drug in the indications acute sinusitis, acute bronchitis und acute urinary tract infection is - with regard to its efficacy comparable to the treatment with standard antibiotics. The application of supportive procedures and the administration of concurrent medication were less expressed in the group treated with the herbal drug. In the above mentioned indications the group treated with the herbal drug displayed a clear advantageous safety profile compared to the group treated with standard antibiotics.
机译:患者和方法:在德国251个中心进行的前瞻性队列研究中,于2004年3月1日至2005年7月30日之间接受了因急性鼻窦炎,支气管炎或尿路感染(UTI)治疗的4岁或以上的患者,当选。如果没有排除标准(严重疾病,需要抗生素治疗,参加另一项试验),则将其纳入研究分析,并进行最终调查。用金盏花药草和辣根含草药药物Angocin Anti-Infekt N(测试组,n = 1223)或标准抗生素治疗(对照组,n = 426)对患者进行治疗。治疗,剂量和治疗持续时间由医生根据患者确定。患有急性鼻窦炎的受试者为536名(408名受试者,对照组128名患者),患有急性支气管炎的受试者为634名受试者(469名受试者,165名对照患者),而来自UTI的受试者为479名受试者(346名受试者,346名受试者)。在研究开始和结束时,由研究者判断症状的严重程度,并用4分(0 =无症状,3种严重症状)进行量化。在治疗过程中,有关患者使用药物,伴随程序和不良事件(AE)的信息。在研究结束时(无疾病或7-14天后),患者返回研究者,记录重要参数,最后根据评分值判断治疗效果和潜在的持续症状。主要疗效标准是通过所有症状的平均相对症状评分变化量化的主诉变化,并与基线值相关。结果:在急性鼻窦炎患者中,平均症状得分相对降低,试验组为81.3%,对照组为84.6%,急性支气管炎患者,平均症状得分为78.3%,对照组为80.3%。对照组,UTI患者的测试组为81.2%,对照组为87.9%。试验组和对照组之间预期减少差异的95%置信区间为:急性鼻窦炎为-8.5%至1.8%,急性支气管炎为7.6%至3.6%,而UTI为-13.1%至-0.1%。对于急性鼻窦炎和支气管炎,可以认为试验治疗的非劣效性,即如果95%置信区间的下限大于10%。在UTI,非自卑水平仅超过3%。试验组的补充程序少于对照组。对于1.5%的受试患者和6.8%的对照患者,观察到AEs。结论:草药治疗急性鼻窦炎,急性支气管炎和急性尿路感染的功效与标准抗生素相当。在使用草药治疗的组中,支持性程序的应用和并发药物的施用较少。在上述适应症中,与标准抗生素治疗组相比,草药治疗组显示出明显的有利安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号